[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"olfaction-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:olfaction-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100467236","olfactory-training-on-smell-dysfunction-patients-in-hk-100467236",false,"NCT05364125","Olfactory Training on Smell Dysfunction Patients in HK","Effect of Olfactory Training on Olfactory Dysfunction Patients in Hong Kong Population","Inclusion Criteria:\n\n* Olfactory dysfunction \\> 6 months and \\\u003C 5 years\n\nExclusion Criteria:\n\n* History of significant head injury (fracture, ICH)\n* History of brain surgery\n* History of nasal surgery\n* Active nasal disease\n* Active neurological disease\n* Poor premorbid status\u002F non-communicable patients\n* Mentally incompetent patients\n* \\\u003C18 years' old\n* Pregnancy\n* Hypersensitivity to the aromatic substance.","ALL","18 Years","70 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","* Causes of olfactory dysfunction can be classified into conductive and sensorineural causes.\n* Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery\n* Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases.\n* Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries.\n* Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study.\n* However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.",[27,28,29,30,31,32,33],"Olfaction Disorders","Smell Disorders","Anosmia","Hyposmia","Olfactory Impairment","Smell Loss","Smell Dysfunction","RECRUITING","2025-05-28",{"date":37,"type":38},"2025-06-03","ACTUAL",{"date":40,"type":38},"2022-07-01",{"date":42,"type":21},"2027-06-30",{"name":44,"class":45},"Pamela Youde Nethersole Eastern Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100561377","study-of-eeg-and-nasal-stimulus-in-olfactory-disorders-100561377","NCT06589375","Study of EEG and Nasal Stimulus in Olfactory Disorders","Neuroscent: EEG Analysis of Cortical Signals Induced by Olfactory Stimuli in Normosmic Subjects and Individuals With Olfactory Disorders, With an In-depth Study of Olfactory Pathways in Patients With Tinnitus","SENSO","Inclusion Criteria:\n\n* Subjects over 18 years of age who have given consent for the collection of specified data, including medical history and personal information, for the purposes of project implementation and in accordance with the ethical standards of the institutions where the project will be conducted.\n\nExclusion Criteria:\n\n* Previous fractures of the facial bones, particularly the ethmoid bone.\n* Active tumors of the brain or face, including tumors of the nose, paranasal sinuses, oral cavity, or nasopharynx.\n* Active nasal-sinus conditions, particularly radiologically proven sinusitis.\n* Mass in the pontocerebellar angle, especially schwannoma of the VIII nerve.\n* Patients with acute and chronic inflammatory diseases of the middle ear, otosclerosis, inner ear diseases (especially Meniere's disease), objective tinnitus, and tinnitus caused by middle ear pathologies and CPA tumors.\n* Neurodegenerative diseases (especially Alzheimer's and Parkinson's disease).\n* Known history of neuropsychiatric or cerebral disorders.\n* Use of psychotropic drugs or drugs active on the central nervous system.\n* Alcohol and drug abuse.",true,{"count":57,"type":21},1000,[24],"Neuroscent aims to analyze EEG signals induced by olfactory stimuli in individuals with normal and impaired olfactory functions, with a focus on patients with tinnitus. The study seeks to develop reliable diagnostic methods using EEG to differentiate between normosmic and hyposmic subjects during olfactory tests, potentially enhancing our understanding of the brain's response to olfactory stimuli. This 24-month interventional study with a device to be patented will involve 1000 participants and aims to establish more effective diagnostic and therapeutic tools for olfactory disorders",[27],[62,63,64,65,66,67,68],"Olfactory stimuli","EEG","Tinnitus","Olfactory disorders","Smell impairment","Olfactometry","Brain waves","NOT_YET_RECRUITING","2024-09-05",{"date":72,"type":38},"2024-09-19",{"date":74,"type":21},"2024-08-31",{"date":76,"type":21},"2026-08-31",{"name":78,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":46},"100392486","phase-2-gnrh-therapy-on-cognition-in-down-syndrome-100392486","NCT04390646","GnRH Therapy on Cognition in Down Syndrome","Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control Study","Inclusion Criteria:\n\n* Diagnosis of trisomy 21\n* Verbal expression (ability to follow the procedures of the study)\n* Consent to a non-hormonal contraception during the whole duration of the study For women: intra-uterine device with copper, a prior tubal ligation or condoms for the partner For men: condoms or vasectomy\n\nExclusion Criteria:\n\n* Acute illness (clinical or biochemical findings suggesting acute illness\u002Fhospitalization)\n* Chronic alcohol abuse, illicit drug use, anabolic steroid abuse, psychotropic drugs reported by caregivers\n* Taking medication that modifies hormones: spironolactone, ketoconazole, anticoagulants, corticosteroids, ACTH hormone, psychotropics, including antidepressants, antipsychotics and anticonvulsants.\n* Known pituitary adenoma and other hormone-dependent tumours\n* Participation in another clinical study\n* Intention to become a parent during the course of the study\n* Females: ovarian cysts, non-hypothalamic anovulation (i.e. polycystic ovary syndrome), pregnancy or lactation\n* Males: hematocrit \\> 54%\n* Contraindications for MRI (e.g. pacemaker, metal clips,etc)\n* Participant or his\u002Fher legal representative do not want to be informed in case of incidental findings","16 Years","50 Years",{"count":89,"type":21},56,[91,92],"PHASE2","PHASE3","Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood.\n\nTo date, there is no treatment available for the cognitive or olfactory defects in DS. The development of an effective treatment targeting cognitive dysfunction in DS adolescents\u002Fadults would be warranted.\n\nGnRH, a decapeptide secreted by hypothalamic neurons is the pilot light of reproduction in all mammals. Pulsatile GnRH acts on the gonadotrophs via the GnRH receptor (GNRHR) in the pituitary gland to stimulate LH and FSH, which themselves will act on the gonads to produce gametes and steroids. However, GNRHR are also expressed in cerebral cortex, hippocampus, amygdala, habenula, olfactory structures, and adrenal gland, suggesting that GnRH may have a role beyond reproduction.\n\nRecently, GnRH has been shown to be involved in the process of ageing and lifespan control. Notably, in murine models, GnRH acts as an anti-ageing factor, independent of sex hormones. While ageing is characterized by hypothalamic inflammation and diminished neurogenesis, particularly in the hypothalamus and the hippocampus, GnRH was able to promote adult neurogenesis.\n\nThe regulation of GnRH secretion is complex and involves hormonal, neuronal input, and environmental factors.\n\nPrévot et al. recently explored cognition within the Ts65Dn model and showed an age-dependent loss of the ability to recognize new objects. Also, these mice exhibit defects in olfaction. Given the role of GnRH in anti-aging mice model, pulsatile GnRH or continuous GnRH infusion (leading to desensitization of the GNRHR) were given to the Ts65Dn mice for two weeks. Amazingly, pulsatile but not continuous GnRH therapy was able to recover cognitive and olfaction defects.",[95,96,97,27],"Down Syndrome","Cognitive Decline","Alzheimer Disease, Early Onset",[99],"GnRH","2024-02-09",{"date":102,"type":38},"2024-02-12",{"date":104,"type":38},"2020-08-27",{"date":106,"type":21},"2028-12",{"name":108,"class":45},"Nelly Pitteloud"]